Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Itolizumab downregulates the synthesis of proinflammatory cytokines and adhesion molecules by inhibiting CD6 leading to lower levels of interferon-γ, interleukin-6, and tumor necrotic factor-α and reduced T-cell infiltration at inflammatory sites. This study aims to compare the effects of tocilizumab and itolizumab in the management of severe coronavirus disease 2019 (COVID-19).Methods: The study population was adults (>18 years) with severe COVID-19 pneumonia admitted to the intensive care unit receiving either tocilizumab or itolizumab during their stay. The primary outcome was clinical improvement (CI), defined as a two-point reduction on a seven-point ordinal scale in the status of the patient from initiating the drug or live discharge. The secondary outcomes were time until CI, improvement in PO2/FiO2 ratio, best PO2/FiO2 ratio, need for mechanical ventilation after administration of study drugs, time to discharge, and survival days.Results: Of the 126 patients included in the study, 92 received tocilizumab and 34 received itolizumab. CI was seen in 46.7% and 61.7% of the patients in the tocilizumab and itolizumab groups, respectively and was not statistically significant (P=0.134). The PO2/FiO2 ratio was significantly better with itolizumab compared to tocilizumab (median [interquartile range]: 315 [200–380] vs. 250 [150–350], P=0.043). The incidence of serious adverse events due to the study drugs was significantly higher with itolizumab compared to tocilizumab (14.7% vs. 3.3%, P=0.032).Conclusions: The CI with itolizumab is similar to tocilizumab. Better oxygenation can be achieved with itolizumab and it can be a substitute for tocilizumab in managing severe COVID-19.
Abstract
Background: Itolizumab downregulates the synthesis of proinflammatory cytokines and adhesion molecules by inhibiting CD6 leading to lower levels of interferon-γ, interleukin-6, and tumor necrotic factor-α and reduced T-cell infiltration at inflammatory sites. This study aims to compare the effects of tocilizumab and itolizumab in the management of severe coronavirus disease 2019 (COVID-19).Methods: The study population was adults (>18 years) with severe COVID-19 pneumonia admitted to the intensive care unit receiving either tocilizumab or itolizumab during their stay. The primary outcome was clinical improvement (CI), defined as a two-point reduction on a seven-point ordinal scale in the status of the patient from initiating the drug or live discharge. The secondary outcomes were time until CI, improvement in PO2/FiO2 ratio, best PO2/FiO2 ratio, need for mechanical ventilation after administration of study drugs, time to discharge, and survival days.Results: Of the 126 patients included in the study, 92 received tocilizumab and 34 received itolizumab. CI was seen in 46.7% and 61.7% of the patients in the tocilizumab and itolizumab groups, respectively and was not statistically significant (P=0.134). The PO2/FiO2 ratio was significantly better with itolizumab compared to tocilizumab (median [interquartile range]: 315 [200–380] vs. 250 [150–350], P=0.043). The incidence of serious adverse events due to the study drugs was significantly higher with itolizumab compared to tocilizumab (14.7% vs. 3.3%, P=0.032).Conclusions: The CI with itolizumab is similar to tocilizumab. Better oxygenation can be achieved with itolizumab and it can be a substitute for tocilizumab in managing severe COVID-19.
참고문헌 (18)
- Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
- Heimfarth L, "Drug repurposing and cytokine management in response to COVID-19 : a review", Int Immunopharmacol, 88, pp.106947~ (2020)
- "Coronavirus (COVID-19) update: FDA authorizes drug for treatment of COVID-19" (2021)[URL]
- REMAP-CAP Investigators, "Interleukin-6 receptor antagonists in critically ill patients with COVID-19", N Engl J Med, 384, pp.1491~1502 (2021)
- RECOVERY Collaborative Group, "Tocilizumab in patients admitted to hospital with COVID-19(RECOVERY) : a randomised, controlled, open-label, platform trial", Lancet, 397, pp.1637~1645 (2021)
- "DCGI gives nod for restricted emergency use to itolizumab for moderate to severe COVID-19 patients" (2020)[URL]
- Loganathan S, "Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications", Expert Opin Biol Ther, 20, pp.1025~1031 (2020)
- Kumari P, "Off-label use of itolizumab in patients with COVID-19 ARDS : our clinical experience in a dedicated COVID center", Indian J Crit Care Med, 25, pp.467~469 (2021)
- "Clinical management protocol: COVID-19" (2020)[URL]
- Lee DW, "Current concepts in the diagnosis and management of cytokine release syndrome", Blood, 124, pp.188~195 (2014)
- Fanelli V, "Acute respiratory distress syndrome : new definition, current and future therapeutic options", J Thorac Dis, 5, pp.326~334 (2013)
- Stone JH, "Efficacy of tocilizumab in patients hospitalized with COVID-19", N Engl J Med, 383, pp.2333~2344 (2020)
- Hermine O, "Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia : a randomized clinical trial", JAMA Intern Med, 181, pp.32~40 (2021)
- Salvarani C, "Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia : a randomized clinical trial", JAMA Intern Med, 181, pp.24~31 (2021)
- "WHO prequalifies first monoclonal antibody - tocilizumab - to treat COVID-19" (2022)[URL]
- "Biocon presented insights into clinical study that enabled DCGI approval of itolizumab for COVID19" (2022)[URL]